氟脱氧葡萄糖PET/MR在未治疗肝内胆管癌中的管理影响
该回顾性研究纳入37例未治疗肝内胆管癌患者,评估PET/MR相对常规影像对临床管理的影响。PET/MR改变了11/37(29.7%)患者的临床管理,其中5例(13.5%)因发现额外病变取消手术,4例(10.8%)「不可手术」患者接受了手术,另2例(5.4%)手术方案显著改变。
要点
- PET/MR改变了29.7%未治疗肝内胆管癌患者的临床管理。
- 5例(13.5%)因PET/MR发现额外病变而取消手术。
- 4例(10.8%)原本「不可手术」患者经PET/MR评估后接受了手术。
核心结论
- 与标准影像相比,PET/MR显著影响了29.7%的未治疗肝内胆管癌患者的治疗计划。
研究设计与样本
- 回顾性分析37例未治疗肝内胆管癌患者的临床病理特征,患者于2015年9月至2018年8月期间接受PET/MR检查,以评估PET/MR相对常规影像对临床管理的影响。
- 37例患者中位年龄63.5岁,20例(54%)为女性,26例同日接受了PET/CT检查,所有患者均为未治疗肝内胆管癌。
主要发现
- 常规影像显示15例为早期可切除病变,22例为超出手术切除范围的晚期病变。
- PET/MR改变了11/37(29.7%)患者的临床管理。
- 5例(13.5%)因发现额外病变而取消手术,4例「不可手术」患者(10.8%)接受了手术。
- 另2例(5.4%)基于PET/MR手术方案发生显著改变。
临床怎么用
- 在未治疗肝内胆管癌患者中,PET/MR可相对常规影像改变临床管理决策,包括取消或实施手术及调整手术方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Intrahepatic cholangiocarcinoma (ICC) is associated with a poor prognosis with surgical resection offering the best chance for long-term survival and potential cure. However, in up to 36% of patients who undergo surgery, more extensive disease is found at time of operation requiring cancellation of surgery. PET/MR is a novel hybrid technology that might improve local and whole-body staging in ICC patients, potentially influencing clinical management. This study was aimed to investigate the possible management implications of PET/MR, relative to conventional imaging, in patients affected by untreated intrahepatic cholangiocarcinoma. METHODS: Retrospective review of the clinicopathologic features of 37 patients with iCCC, who underwent PET/MR between September 2015 and August 2018, was performed to investigate the management implications that PET/MR had exerted on the affected patients, relative to conventional imaging. RESULTS: Of the 37 patients enrolled, median age 63.5 years, 20 (54%) were female. The same day PET/CT was performed in 26 patients. All patients were iCCC-treatment-naïve. Conventional imaging obtained as part of routine clinical care demonstrated early-stage resectable disease for 15 patients and advanced stage disease beyond the scope of surgical resection for 22. PET/MR modified the clinical management of 11/37 (29.7%) patients: for 5 patients (13.5%), the operation was cancelled due to identification of additional disease, while 4 "inoperable" patients (10.8%) underwent an operation. An additional 2 patients (5.4%) had a significant change in their operative plan based on PET/MR. CONCLUSIONS: When compared with standard imaging, PET/MR significantly influenced the treatment plan in 29.7% of patients with iCCC. TRIAL REGISTRATION: 2018P001334.
引用
- Ferrone C, Goyal L, Qadan M, et al. Management implications of fluorodeoxyglucose positron emission tomography/magnetic resonance in untreated intrahepatic cholangiocarcinoma. Eur J Nucl Med Mol Imaging. 2019. PMID: 31705172. doi:10.1007/s00259-019-04558-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。